(Q43430988)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22048230%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22048230%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22048230%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Sebastian Schneeweiss

series ordinal

1

object named as

S Schneeweiss

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22048230%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

3

R J Glynn

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22048230%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

2

J J Gagne

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22048230%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

M Ruhl

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22048230%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

language of work or name

English

0 references

publication date

2 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22048230%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22048230%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

90

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22048230%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22048230%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

777-790

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22048230%20AND%20SRC:MED&resulttype=core&format=json

Developments in post-marketing comparative effectiveness research

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Availability of comparative efficacy data at the time of drug approval in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Use of ezetimibe in the United States and Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

A review of uses of health care utilization databases for epidemiologic research on therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Impact of asthma controller medications on clinical, economic, and patient-reported outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Randomized, controlled trials, observational studies, and the hierarchy of research designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

A basic study design for expedited safety signal evaluation based on electronic healthcare data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Preference-based instrumental variable methods for the estimation of treatment effects: assessing validity and interpreting results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Instrumental variable analysis for estimation of treatment effects with dichotomous outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Physician and practice characteristics associated with the early utilization of new prescription drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

The medical license number accurately identifies the prescribing physician in a large pharmacy claims database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

A simulation study of the number of events per variable in logistic regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Estimating causal effects from large data sets using propensity scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

The risk of infection associated with tumor necrosis factor alpha antagonists: making sense of epidemiologic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Instrumental variable methods in comparative safety and effectiveness research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Clinical consequences of generic warfarin substitution: an ecological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Utilizing Medicare claims data for real‐time drug safety evaluations:is it feasible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

The importance of anaemia in diagnosing colorectal cancer: a case-control study using electronic primary care records

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Multiple imputation for missing laboratory data: an example from infectious disease epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Developing the Sentinel System--a national resource for evidence development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Use of propensity score technique to account for exposure-related covariates: an example and lesson

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

High-dimensional propensity score adjustment in studies of treatment effects using health care claims data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Evaluating Medication Effects Outside of Clinical Trials: New-User Designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Celecoxib for the prevention of colorectal adenomatous polyps

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Clinical trial simulation: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Validation of the Archimedes Diabetes Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

Portfolio selection and management in pharmaceutical research and development: issues and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

7 January 2021

Comparative effectiveness: the fourth hurdle in drug development and a role for clinical pharmacology

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

7 January 2021

Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

7 January 2021

Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

7 January 2021

Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

7 January 2021

Simultaneously assessing intended and unintended treatment effects of multiple treatment options: a pragmatic "matrix design"

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

7 January 2021

Self-selected posttrial aspirin use and subsequent cardiovascular disease and mortality in the physicians' health study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

7 January 2021

Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

7 January 2021

Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

7 January 2021

What we can learn from a decision model: comment on "Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management"

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.235

7 January 2021